- Home
- PTON vs RARE Comparison
PTON vs RARE Comparison
Compare PTON & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTON | RARE |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PTON | RARE |
|---|---|---|
| Price | $6.40 | $36.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $9.68 | ★ $85.20 |
| AVG Volume (30 Days) | ★ 10.2M | 1.3M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,455,600,000.00 | $630,598,000.00 |
| Revenue This Year | $1.53 | $19.09 |
| Revenue Next Year | $1.42 | $20.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.63 |
| 52 Week Low | $4.63 | $25.81 |
| 52 Week High | $10.90 | $50.00 |
Technical Indicators
Market Signals| Indicator | PTON | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 62.08 |
| Support Level | $6.37 | $33.16 |
| Resistance Level | $6.80 | $34.77 |
| Average True Range (ATR) | 0.32 | 1.52 |
| MACD | -0.02 | 0.36 |
| Stochastic Oscillator | 9.29 | 83.52 |
Price Performance
Historical ComparisonAbout PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product derives revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.